Figure S5: Results for each follow-up interverval, longest follow-up, and subgroup analyses

Analyses included

Analysis 1: ER (number); results at longest follow-up
Analysis 2: ER (number); at each follow-up interval
Analysis 3: ER (number); focus of visit subgroups
Analysis 4: ER (number); age of participants subgroups
Analysis 5: ER (number); type of visitor subgroups
Analysis 6: ER (number); number of visits subgroups
Analysis 7: ER (people); results at longest follow-up
Analysis 8: ER (people); at each follow-up interval
Analysis 9: ER (people); focus of visit subgroups
Analysis 10: ER (people); age of participants subgroups
Analysis 11: ER (people); type of visitor subgroups
Analysis 12: ER (people); number of visits subgroups
Analysis 13: Falls (number); results at longest follow-up
Analysis 14: Falls (number); at each follow-up interval
Analysis 15: Falls (number); focus of visit subgroups
Analysis 16: Falls (number); age of participants subgroups
Analysis 17: Falls (number); type of visitor subgroups
Analysis 18: Falls (number); number of visits subgroups
Analysis 19: Falls (people) at each follow-up interval
Analysis 20: Falls (people); focus of visit subgroups
Analysis 21: Falls (people); age of participants subgroups
Analysis 22: Falls (people); type of visitor subgroups
Analysis 23: Falls (people); number of visits subgroups
Analysis 24: Falls (subjective), results at longest follow-up
Analysis 25: Falls (subjective) at each follow-up interval
Analysis 26: Falls (subjective); focus of visit subgroups
Analysis 27: Falls (subjective); age of participants subgroups
Analysis 28: Falls (subjective); type of visitor subgroups
Analysis 29: Falls (subjective); number of visits subgroups
Analysis 30: Functioning ADL/IADL at each follow-up interval
Analysis 31: Functioning ADL/IADL; focus of visit subgroups
Analysis 32: Functioning ADL/IADL; age of participants subgroups
Analysis 33: Functioning ADL/IADL; type of visitor subgroups
Analysis 34: Functioning ADL/IADL; number of visits subgroups
Analysis 35: Cognitive functioning, results at longest follow-up
Analysis 36: Quality of life at each follow-up interval
Analysis 37: Quality of life; focus of visit subgroups
Analysis 38: Quality of life; age of participants subgroups
Analysis 39: Quality of life; type of visitor subgroups
Analysis 40: Quality of life; number of visits subgroups
Analysis 41: Hospitalisation Admissions, results at longest follow-up
Analysis 42: Hospitalisation Admissions at each follow-up interval
Analysis 43: Hospitalisation Admissions; focus of visit subgroups
Analysis 44: Hospitalisation Admissions; age of participants subgroups
Analysis 45: Hospitalisation Admissions; type of visitor subgroups
Analysis 46: Hospitalisation Admissions; number of visits subgroups
Analysis 47: Hospitalisation (days), results at longest follow-up
Analysis 48: Hospitalisation (days) at each follow-up interval
Analysis 49: Hospitalisation (days); focus of visit subgroups
Analysis 50: Hospitalisation (days); age of participants subgroups
Analysis 51: Hospitalisation (days); type of visitor subgroups
Analysis 52: Hospitalisation (days); number of visits subgroups
Analysis 53: Hospitalisation (people) at each follow-up interval
Analysis 54: Hospitalisation (people); focus of visit subgroups
Analysis 55: Hospitalisation (people); age of participants subgroups
Analysis 56: Hospitalisation (people); type of visitor subgroups
Analysis 57: Hospitalisation (people); number of visits subgroups
Analysis 58: Injuries (number), results at longest follow-up
Analysis 59: Injuries (people), results at longest follow-up
Analysis 60: Injuries (people) at each follow-up interval
Analysis 61: Injuries (people); focus of visit subgroups
Analysis 62: Injuries (people); age of participants subgroups

Analysis 1: ER (number); results at longest follow-up



Analysis 2: ER (number); at each follow-up interval



Analysis 3: ER (number); focus of visit subgroups



Analysis 4: ER (number); age of participants subgroups



Analysis 5: ER (number); type of visitor subgroups



Analysis 6: ER (number); number of visits subgroups



Analysis 7: ER (people); results at longest follow-up



Analysis 8: ER (people); at each follow-up interval



Analysis 9: ER (people); focus of visit subgroups



Analysis 10: ER (people); age of participants subgroups



Analysis 11: ER (people); type of visitor subgroups



Analysis 12: ER (people); number of visits subgroups



Analysis 13: Falls (number); results at longest follow-up



Analysis 14: Falls (number); at each follow-up interval



Analysis 15: Falls (number); focus of visit subgroups



Analysis 16: Falls (number); age of participants subgroups



Analysis 17: Falls (number); type of visitor subgroups



Analysis 18: Falls (number); number of visits subgroups



Analysis 19: Falls (people) at each follow-up interval



Analysis 20: Falls (people); focus of visit subgroups



Analysis 21: Falls (people); age of participants subgroups



Analysis 22: Falls (people); type of visitor subgroups



Analysis 23: Falls (people); number of visits subgroups



Analysis 24: Falls (subjective), results at longest follow-up



Analysis 25: Falls (subjective) at each follow-up interval



Analysis 26: Falls (subjective); focus of visit subgroups



Analysis 27: Falls (subjective); age of participants subgroups



Analysis 28: Falls (subjective); type of visitor subgroups



Analysis 29: Falls (subjective); number of visits subgroups



Analysis 30: Functioning ADL/IADL at each follow-up interval



Analysis 31: Functioning ADL/IADL; focus of visit subgroups



Analysis 32: Functioning ADL/IADL; age of participants subgroups



Analysis 33: Functioning ADL/IADL; type of visitor subgroups



Analysis 34: Functioning ADL/IADL; number of visits subgroups



Analysis 35: Cognitive functioning, results at longest follow-up



Study or Subgroup	Std. Mean Difference	SE	Home visits Total	Control Total	Weight	Std. Mean Difference IV, Random, 95% CI
Newbury 2001	-0.46767489	0.3253822	45	44	4.5%	-0.47 [-1.11, 0.17]
Liu-Ambrose 2008	-0.34338806	0.27646923	28	24	5.9%	-0.34 [-0.89, 0.20]
Markle-Reid 2010	-0.1247856	0.21554978	45	40	8.7%	-0.12 [-0.55, 0.30]
Bernabei 1998	-0.31937041	0.15149675	88	87	13.6%	-0.32 [-0.62, -0.02]
Luukinen 2006	-0.12372351	0.14274132	144	150	14.5%	-0.12 [-0.40, 0.16]
Thomas 2007	0	0.12057725	204	103	17.1%	0.00 [-0.24, 0.24]
Bouman 2008	0.15832071	0.116876	139	154	17.6%	0.16 [-0.07, 0.39]
Davison 2005	0.14794968	0.11294314	159	154	18.1%	0.15 [-0.07, 0.37]
Total (95% CI)			**852**	**756**	**100.0%**	**-0.06 [-0.21, 0.09]**

Heterogeneity: Tau² = 0.02; Chi² = 12.49, df = 7 (P = 0.09); I² = 44%
Test for overall effect: Z = 0.79 (P = 0.43)

Analysis 36: Quality of life at each follow-up interval



Study or Subgroup	Std. Mean Difference	SE	Home visits Total	Control Total	Weight	Std. Mean Difference IV, Random, 95% CI
1.44.1 01-11 months						
Crawford Shearer 2010	-0.15973573	0.30370371	20	22	3.5%	-0.16 [-0.75, 0.44]
Lin 2007	-0.68159697	0.22962498	39	40	5.6%	-0.68 [-1.13, -0.23]
Kingston 2001	0.11056703	0.20878628	51	41	6.5%	0.11 [-0.30, 0.52]
Markle-Reid 2010	0.05052332	0.2072482	49	43	6.6%	0.05 [-0.36, 0.46]
Lenaghan 2007	0.29405032	0.20177338	50	49	6.9%	0.29 [-0.10, 0.69]
Gallagher 1996	-0.11156514	0.1986222	50	50	7.1%	-0.11 [-0.50, 0.28]
Hendriks 2008	0.0032602	0.13291559	131	143	12.5%	0.00 [-0.26, 0.26]
Markle-Reid 2006	-0.04768252	0.12860815	120	121	13.0%	-0.05 [-0.30, 0.20]
van Hout 2010	-0.00521267	0.09189674	244	229	18.4%	-0.01 [-0.19, 0.17]
Holland 2005	-0.16162187	0.08257294	307	282	20.0%	-0.16 [-0.32, 0.00]
Subtotal (95% CI)			**1061**	**1020**	**100.0%**	**-0.06 [-0.18, 0.06]**
Heterogeneity: Tau² = 0.01; Chi² = 13.62, df = 9 (P = 0.14); I² = 34%						
Test for overall effect: Z = 1.00 (P = 0.32)						
1.44.2 12-23 months						
Shapiro 2002	-0.4934019	0.28080567	32	21	1.2%	-0.49 [-1.04, 0.06]
Newbury 2001	-0.07936562	0.21500223	45	43	2.1%	-0.08 [-0.50, 0.34]
Balaban 1988	0.16224858	0.2146303	40	46	2.1%	0.16 [-0.26, 0.58]
Luukinen 2006	0.13024238	0.16854423	144	150	3.4%	0.13 [-0.20, 0.46]
Pighills 2011	-0.00959988	0.15525892	87	78	4.0%	-0.01 [-0.31, 0.29]
Hendriks 2008	-0.05194913	0.13624672	124	134	5.2%	-0.05 [-0.32, 0.22]
van Haastregt 2000	-0.01953552	0.13007778	120	115	5.7%	-0.02 [-0.27, 0.24]
Bouman 2008	0.01359048	0.11680754	139	154	7.0%	0.01 [-0.22, 0.24]
Yamada 2003	-0.10274656	0.11364501	160	149	7.4%	-0.10 [-0.33, 0.12]
Ploeg 2010	-0.10764642	0.10764642	328	310	8.3%	-0.11 [-0.32, 0.10]
Sommers 2000	-0.17900004	0.10217801	201	183	9.2%	-0.18 [-0.38, 0.02]
Thomas 2007	-0.10686591	0.10156366	299	143	9.3%	-0.11 [-0.31, 0.09]
van Hout 2010	0.13887444	0.09708599	215	209	10.2%	0.14 [-0.05, 0.33]
Hebert 2001	0.03384274	0.09270438	233	231	11.2%	0.03 [-0.15, 0.22]
van Rossum 1993	-0.04554753	0.08295043	292	288	13.9%	-0.05 [-0.21, 0.12]
Subtotal (95% CI)			**2459**	**2254**	**100.0%**	**-0.03 [-0.10, 0.03]**
Heterogeneity: Tau² = 0.00; Chi² = 11.82, df = 14 (P = 0.62); I² = 0%						
Test for overall effect: Z = 1.11 (P = 0.27)						
1.44.3 24-35 months						
Bouman 2008	-0.05872679	0.11674329	139	154	8.4%	-0.06 [-0.29, 0.17]
Thomas 2007	-0.09979879	0.11006239	253	122	9.3%	-0.10 [-0.32, 0.12]
Vetter 1984a	-0.10632843	0.09988346	201	199	10.8%	-0.11 [-0.30, 0.09]
Vetter 1984b	-0.16945091	0.09477957	237	210	11.8%	-0.17 [-0.36, 0.02]
Sorensen 1988	-0.06084525	0.07678877	315	366	16.1%	-0.06 [-0.21, 0.09]
Counsell 2007	0.09213862	0.06485754	474	477	20.1%	0.09 [-0.03, 0.22]
Byles 2004	-0.11914883	0.05635457	779	529	23.7%	-0.12 [-0.23, -0.01]
Subtotal (95% CI)			**2398**	**2057**	**100.0%**	**-0.07 [-0.14, 0.01]**
Heterogeneity: Tau² = 0.00; Chi² = 8.28, df = 6 (P = 0.22); I² = 28%						
Test for overall effect: Z = 1.77 (P = 0.08)						
1.44.4 36+ months						
Thomas 2007	-0.05336521	0.12059648	204	103	11.9%	-0.05 [-0.29, 0.18]
Pathy 1992	-0.17854933	0.09792811	223	196	18.0%	-0.18 [-0.37, 0.01]
van Rossum 1993	-0.04554753	0.08295043	292	288	25.1%	-0.05 [-0.21, 0.12]
Byles 2004	-0.14951835	0.06180403	636	446	45.1%	-0.15 [-0.27, -0.03]
Subtotal (95% CI)			**1355**	**1033**	**100.0%**	**-0.12 [-0.20, -0.04]**
Heterogeneity: Tau² = 0.00; Chi² = 1.69, df = 3 (P = 0.64); I² = 0%						
Test for overall effect: Z = 2.83 (P = 0.005)						

Analysis 37: Quality of life; focus of visit subgroups



Analysis 38: Quality of life; age of participants subgroups



Analysis 39: Quality of life; type of visitor subgroups



Analysis 40: Quality of life; number of visits subgroups



Analysis 41: Hospitalisation admissions, results at longest follow-up



Study or Subgroup	log[Rate Ratio]	SE	Home visits Total	Control Total	Weight	Rate Ratio IV, Random, 95% CI
Lightbody 2002	-0.210405	0.474342	155	159	1.9%	0.81 [0.32, 2.05]
Lenaghan 2007	-0.07195722	0.31244047	68	66	3.9%	0.93 [0.50, 1.72]
Caplan 2004	-0.48954823	0.29135827	370	369	4.3%	0.61 [0.35, 1.08]
Dalby 2000	0.27287577	0.28986801	70	69	4.4%	1.31 [0.74, 2.32]
Tinetti 1994	-0.31480238	0.19720266	153	148	7.3%	0.73 [0.50, 1.07]
Balaban 1988	0.59420569	0.18601026	103	95	7.8%	1.81 [1.26, 2.61]
Close 1999	-0.20134241	0.15748661	184	213	9.2%	0.82 [0.60, 1.11]
Sommers 2000	0.13693273	0.13824932	238	227	10.3%	1.15 [0.87, 1.50]
Pathy 1992	-0.12503838	0.13131131	219	200	10.7%	0.88 [0.68, 1.14]
Pathy 1992	-0.13916677	0.11309618	150	156	11.8%	0.87 [0.70, 1.09]
van Rossum 1993	-0.32160726	0.09614351	292	288	12.9%	0.72 [0.60, 0.88]
Counsell 2007	-0.05338644	0.05272497	474	477	15.6%	0.95 [0.85, 1.05]
Total (95% CI)			**2476**	**2467**	**100.0%**	**0.93 [0.81, 1.06]**

Heterogeneity: Tau² = 0.03; Chi² = 28.07, df = 11 (P = 0.003); I² = 61%
Test for overall effect: Z = 1.10 (P = 0.27)

Analysis 42: Hospitalisation admissions at each follow-up interval



Study or Subgroup	log[Rate Ratio]	SE	Home visits Total	Control Total	Weight	Rate Ratio IV, Random, 95% CI
1.50.1 01-11 months						
Lightbody 2002	-0.210405	0.474342	155	159	16.8%	0.81 [0.32, 2.05]
Lenaghan 2007	-0.07195722	0.31244047	68	66	38.7%	0.93 [0.50, 1.72]
Caplan 2004	-0.48954823	0.29135827	370	369	44.5%	0.61 [0.35, 1.08]
Subtotal (95% CI)			**593**	**594**	**100.0%**	**0.75 [0.52, 1.11]**
Heterogeneity: Tau² = 0.00; Chi² = 0.98, df = 2 (P = 0.61); I² = 0%						
Test for overall effect: Z = 1.45 (P = 0.15)						
1.50.2 12-23 months						
Dalby 2000	0.27287577	0.28986801	70	69	9.0%	1.31 [0.74, 2.32]
Tinetti 1994	-0.31480238	0.19720266	153	148	13.0%	0.73 [0.50, 1.07]
Balaban 1988	0.59420569	0.18601026	103	95	13.6%	1.81 [1.26, 2.61]
van Rossum 1993	-0.415743	0.16824	292	288	14.5%	0.66 [0.47, 0.92]
Close 1999	-0.20134241	0.15748661	184	213	15.1%	0.82 [0.60, 1.11]
Sommers 2000	0.10222723	0.15102741	238	227	15.4%	1.11 [0.82, 1.49]
Counsell 2007	0.074388	0.073467	474	477	19.3%	1.08 [0.93, 1.24]
Subtotal (95% CI)			**1514**	**1517**	**100.0%**	**1.00 [0.80, 1.26]**
Heterogeneity: Tau² = 0.06; Chi² = 22.70, df = 6 (P = 0.0009); I² = 74%						
Test for overall effect: Z = 0.03 (P = 0.97)						
1.50.3 24-35 months						
Sommers 2000	0.13693273	0.13824932	238	227	28.2%	1.15 [0.87, 1.50]
van Rossum 1993	-0.3740302	0.11381009	292	288	31.7%	0.69 [0.55, 0.86]
Counsell 2007	-0.05338644	0.05272497	474	477	40.1%	0.95 [0.85, 1.05]
Subtotal (95% CI)			**1004**	**992**	**100.0%**	**0.90 [0.71, 1.15]**
Heterogeneity: Tau² = 0.04; Chi² = 9.39, df = 2 (P = 0.009); I² = 79%						
Test for overall effect: Z = 0.82 (P = 0.41)						
1.50.4 36+ months						
Pathy 1992	-0.12503838	0.13131131	219	200	24.3%	0.88 [0.68, 1.14]
Pathy 1992	-0.13916677	0.11309618	150	156	32.2%	0.87 [0.70, 1.09]
van Rossum 1993	-0.32160726	0.09614351	292	288	43.4%	0.72 [0.60, 0.88]
Subtotal (95% CI)			**661**	**644**	**100.0%**	**0.81 [0.71, 0.92]**
Heterogeneity: Tau² = 0.00; Chi² = 2.15, df = 2 (P = 0.34); I² = 7%						
Test for overall effect: Z = 3.23 (P = 0.001)						

Analysis 43: Hospitalisation admissions; focus of visit subgroups



Analysis 44: Hospitalisation admissions; age of participants subgroups



Analysis 45: Hospitalisation admissions; type of visitor subgroups



Analysis 46: Hospitalisation admissions; number of visits subgroups



Analysis 47: Hospitalisation (days), results at longest follow-up



Analysis 48: Hospitalisation (days) at each follow-up interval



Analysis 49: Hospitalisation (days); focus of visit subgroups



Analysis 50: Hospitalisation (days); age of participants subgroups



Analysis 51: Hospitalisation (days); type of visitor subgroups



Analysis 52: Hospitalisation (days); number of visits subgroups



Analysis 53: Hospitalisation (people) at each follow-up interval



Analysis 54: Hospitalisation (people); focus of visit subgroups



Analysis 55: Hospitalisation (people); age of participants subgroups



Analysis 56: Hospitalisation (people); type of visitor subgroups



Analysis 57: Hospitalisation (people); number of visits subgroups



Analysis 58: Injuries (number), results at longest follow-up



Analysis 59: Injuries (people), results at longest follow-up



Analysis 60: Injuries (people) at each follow-up interval



Analysis 61: Injuries (people); focus of visit subgroups



Analysis 62: Injuries (people); age of participants subgroups



Analysis 63: Injuries (people); type of visitor subgroups



Analysis 64: Injuries (people); number of visits subgroups



Analysis 65: Institutionalisation (days), results at longest follow-up



Analysis 66: Institutionalisation (people) at each follow-up interval



Analysis 67: Institutionalisation (people); focus of visit subgroups



Analysis 68: Institutionalisation (people); age of participants subgroups



Analysis 69: Institutionalisation (people); type of visitor subgroups



Analysis 70: Institutionalisation (people); number of visits subgroups



Analysis 71: Mortality (Focus of visits subgroups)



Analysis 72: Mortality; age of participants subgroups



Analysis 73: Mortality; type of visitor subgroups



Analysis 74: Mortality; number of visits subgroups



Analysis 75: Psychiatric (anxiety and depression), results at longest follow-up



Study or Subgroup	Std. Mean Difference	SE	Home visits Total	Control Total	Weight	Std. Mean Difference IV, Random, 95% CI
Shapiro 2002	-0.38438454	0.27919357	32	21	2.1%	-0.38 [-0.93, 0.16]
Kono 2004	-0.1249206	0.26073557	32	26	2.3%	-0.12 [-0.64, 0.39]
Lin 2007	-0.21979435	0.22352157	39	40	3.1%	-0.22 [-0.66, 0.22]
Balaban 1988	-0.04008557	0.21429989	40	46	3.3%	-0.04 [-0.46, 0.38]
Markle-Reid 2010	0.14926786	0.20750508	49	43	3.5%	0.15 [-0.26, 0.56]
Ciechanowski 2004	-0.34318576	0.17798035	67	60	4.6%	-0.34 [-0.69, 0.01]
Bernabei 1998	-0.40447154	0.15207651	88	87	6.0%	-0.40 [-0.70, -0.11]
Luukinen 2006	-0.10410841	0.1411547	144	150	6.7%	-0.10 [-0.38, 0.17]
Markle-Reid 2006	0.01619677	0.13202045	113	115	7.5%	0.02 [-0.24, 0.27]
Hendriks 2008	0.05020461	0.12426243	124	134	8.2%	0.05 [-0.19, 0.29]
Bouman 2008	-0.08667185	0.11676946	139	154	9.0%	-0.09 [-0.32, 0.14]
Kono 2011	-0.02557471	0.11102786	161	162	9.6%	-0.03 [-0.24, 0.19]
Sommers 2000	-0.06566503	0.10200118	201	183	10.8%	-0.07 [-0.27, 0.13]
Vetter 1984a	-0.28999705	0.09935649	206	202	11.2%	-0.29 [-0.48, -0.10]
Vetter 1984b	0.05857493	0.09322435	241	219	12.1%	0.06 [-0.12, 0.24]
Total (95% CI)			**1676**	**1642**	**100.0%**	**-0.10 [-0.18, -0.02]**

Heterogeneity: $Tau^2 = 0.01$; $Chi^2 = 18.06$, df = 14 (P = 0.20); $I^2 = 22\%$
Test for overall effect: Z = 2.37 (P = 0.02)

Analysis 76: Psychiatric (anxiety and depression) at each follow-up interval



Study or Subgroup	Std. Mean Difference	SE	Home visits Total	Control Total	Weight	Std. Mean Difference IV, Random, 95% CI
2.95.1 01-11 months						
Lin 2007	-0.21979435	0.22352157	39	40	17.3%	-0.22 [-0.66, 0.22]
Markle-Reid 2010	0.14926786	0.20750508	49	43	18.2%	0.15 [-0.26, 0.56]
Ciechanowski 2004	-0.80517631	0.18094344	69	62	19.6%	-0.81 [-1.16, -0.45]
Markle-Reid 2006	0.01619677	0.13202045	113	115	22.2%	0.02 [-0.24, 0.27]
Hendriks 2008	0.04129397	0.12061958	131	143	22.7%	0.04 [-0.20, 0.28]
Subtotal (95% CI)			**401**	**403**	**100.0%**	**-0.16 [-0.47, 0.16]**
Heterogeneity: $Tau^2 = 0.10$; $Chi^2 = 19.05$, df = 4 (P = 0.0008); $I^2 = 79\%$						
Test for overall effect: Z = 0.97 (P = 0.33)						
2.95.2 12-23 months						
Shapiro 2002	-0.38438454	0.27919357	32	21	3.4%	-0.38 [-0.93, 0.16]
Kono 2004	-0.1249206	0.26073557	32	26	3.9%	-0.12 [-0.64, 0.39]
Balaban 1988	-0.04008557	0.21429989	40	46	5.8%	-0.04 [-0.46, 0.38]
Ciechanowski 2004	-0.34318576	0.17798035	67	60	8.3%	-0.34 [-0.69, 0.01]
Bernabei 1998	-0.40447154	0.15207651	88	87	11.2%	-0.40 [-0.70, -0.11]
Luukinen 2006	-0.10410841	0.1411547	144	150	12.9%	-0.10 [-0.38, 0.17]
Hendriks 2008	0.05020461	0.12426243	124	134	16.3%	0.05 [-0.19, 0.29]
Bouman 2008	-0.0923089	0.11675516	139	154	18.3%	-0.09 [-0.32, 0.14]
Kono 2011	-0.04926539	0.11104022	161	162	20.0%	-0.05 [-0.27, 0.17]
Subtotal (95% CI)			**827**	**840**	**100.0%**	**-0.13 [-0.23, -0.02]**
Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 8.45$, df = 8 (P = 0.39); $I^2 = 5\%$						
Test for overall effect: Z = 2.41 (P = 0.02)						
2.95.3 24-35 months						
Bouman 2008	-0.08667185	0.11676946	139	154	17.4%	-0.09 [-0.32, 0.14]
Kono 2011	-0.02557471	0.11102786	161	162	18.5%	-0.03 [-0.24, 0.19]
Sommers 2000	-0.06566503	0.10200118	201	183	20.5%	-0.07 [-0.27, 0.13]
Vetter 1984a	-0.28999705	0.09935649	206	202	21.1%	-0.29 [-0.48, -0.10]
Vetter 1984b	0.05857493	0.09322435	241	219	22.6%	0.06 [-0.12, 0.24]
Subtotal (95% CI)			**948**	**920**	**100.0%**	**-0.08 [-0.20, 0.04]**
Heterogeneity: $Tau^2 = 0.01$; $Chi^2 = 6.94$, df = 4 (P = 0.14); $I^2 = 42\%$						
Test for overall effect: Z = 1.32 (P = 0.19)						

Analysis 77: Psychiatric (anxiety and depression); focus of visit subgroups



Study or Subgroup	Std. Mean Difference	SE	Home visits Total	Control Total	Weight	Std. Mean Difference IV, Random, 95% CI
2.96.1 Falls Only						
Lin 2007	−0.21979435	0.22352157	39	40	3.1%	−0.22 [−0.66, 0.22]
Luukinen 2006	−0.10410841	0.1411547	144	150	6.7%	−0.10 [−0.38, 0.17]
Subtotal (95% CI)			**183**	**190**	**9.8%**	**−0.14 [−0.37, 0.10]**
Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 0.19$, df = 1 (P = 0.66); $I^2 = 0\%$						
Test for overall effect: Z = 1.15 (P = 0.25)						
2.96.2 MGA Only						
Shapiro 2002	−0.38438454	0.27919357	32	21	2.1%	−0.38 [−0.93, 0.16]
Kono 2004	−0.1249206	0.26073557	32	26	2.3%	−0.12 [−0.64, 0.39]
Balaban 1988	−0.04008557	0.21429989	40	46	3.3%	−0.04 [−0.46, 0.38]
Bernabei 1998	−0.40447154	0.15207651	88	87	6.0%	−0.40 [−0.70, −0.11]
Markle-Reid 2006	0.01619677	0.13202045	113	115	7.5%	0.02 [−0.24, 0.27]
Bouman 2008	−0.08667185	0.11676946	139	154	9.0%	−0.09 [−0.32, 0.14]
Kono 2011	−0.02557471	0.11102786	161	162	9.6%	−0.03 [−0.24, 0.19]
Sommers 2000	−0.06566503	0.10200118	201	183	10.8%	−0.07 [−0.27, 0.13]
Vetter 1984a	−0.28999705	0.09935649	206	202	11.2%	−0.29 [−0.48, −0.10]
Vetter 1984b	0.05857493	0.09322435	241	219	12.1%	0.06 [−0.12, 0.24]
Subtotal (95% CI)			**1253**	**1215**	**73.8%**	**−0.11 [−0.21, −0.01]**
Heterogeneity: $Tau^2 = 0.01$; $Chi^2 = 13.03$, df = 9 (P = 0.16); $I^2 = 31\%$						
Test for overall effect: Z = 2.11 (P = 0.04)						
2.96.3 Both						
Markle-Reid 2010	0.14926786	0.20750508	49	43	3.5%	0.15 [−0.26, 0.56]
Hendriks 2008	0.05020461	0.12426243	124	134	8.2%	0.05 [−0.19, 0.29]
Subtotal (95% CI)			**173**	**177**	**11.7%**	**0.08 [−0.13, 0.29]**
Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 0.17$, df = 1 (P = 0.68); $I^2 = 0\%$						
Test for overall effect: Z = 0.72 (P = 0.47)						
2.96.4 Neither						
Ciechanowski 2004	−0.34318576	0.17798035	67	60	4.6%	−0.34 [−0.69, 0.01]
Subtotal (95% CI)			**67**	**60**	**4.6%**	**−0.34 [−0.69, 0.01]**
Heterogeneity: Not applicable						
Test for overall effect: Z = 1.93 (P = 0.05)						
Total (95% CI)			**1676**	**1642**	**100.0%**	**−0.10 [−0.18, −0.02]**
Heterogeneity: $Tau^2 = 0.01$; $Chi^2 = 18.06$, df = 14 (P = 0.20); $I^2 = 22\%$						
Test for overall effect: Z = 2.37 (P = 0.02)						
Test for subgroup differences: $Chi^2 = 4.71$, df = 3 (P = 0.19), $I^2 = 36.3\%$						

Analysis 78: Psychiatric (anxiety and depression); age of participants subgroups



Study or Subgroup	Std. Mean Difference	SE	Home visits Total	Control Total	Weight	Std. Mean Difference IV, Random, 95% CI
2.97.1 <=70						
Balaban 1988	−0.04008557	0.21429989	40	46	3.4%	−0.04 [−0.46, 0.38]
Subtotal (95% CI)			**40**	**46**	**3.4%**	**−0.04 [−0.46, 0.38]**
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.19 (P = 0.85)						
2.97.2 71-75						
Ciechanowski 2004	−0.34318576	0.17798035	67	60	4.7%	−0.34 [−0.69, 0.01]
Hendriks 2008	0.05020461	0.12426243	124	134	8.5%	0.05 [−0.19, 0.29]
Subtotal (95% CI)			**191**	**194**	**13.2%**	**−0.13 [−0.51, 0.26]**
Heterogeneity: $Tau^2 = 0.05$; $Chi^2 = 3.28$, df = 1 (P = 0.07); $I^2 = 70\%$						
Test for overall effect: Z = 0.64 (P = 0.52)						
2.97.3 76-80						
Shapiro 2002	−0.38438454	0.27919357	32	21	2.1%	−0.38 [−0.93, 0.16]
Lin 2007	−0.21979435	0.22352157	39	40	3.2%	−0.22 [−0.66, 0.22]
Bouman 2008	−0.08667185	0.11676946	139	154	9.3%	−0.09 [−0.32, 0.14]
Kono 2011	−0.02557471	0.11102786	161	162	10.0%	−0.03 [−0.24, 0.19]
Sommers 2000	−0.06566503	0.10200118	201	183	11.2%	−0.07 [−0.27, 0.13]
Vetter 1984a	−0.28999705	0.09935649	206	202	11.6%	−0.29 [−0.48, −0.10]
Vetter 1984b	0.05857493	0.09322435	241	219	12.6%	0.06 [−0.12, 0.24]
Subtotal (95% CI)			**1019**	**981**	**60.1%**	**−0.10 [−0.21, 0.01]**
Heterogeneity: $Tau^2 = 0.01$; $Chi^2 = 8.43$, df = 6 (P = 0.21); $I^2 = 29\%$						
Test for overall effect: Z = 1.80 (P = 0.07)						
2.97.4 81-85						
Kono 2004	−0.1249206	0.26073557	32	26	2.4%	−0.12 [−0.64, 0.39]
Bernabei 1998	−0.40447154	0.15207651	88	87	6.2%	−0.40 [−0.70, −0.11]
Markle-Reid 2006	0.01619677	0.13202045	113	115	7.7%	0.02 [−0.24, 0.27]
Subtotal (95% CI)			**233**	**228**	**16.3%**	**−0.17 [−0.46, 0.12]**
Heterogeneity: $Tau^2 = 0.03$; $Chi^2 = 4.38$, df = 2 (P = 0.11); $I^2 = 54\%$						
Test for overall effect: Z = 1.16 (P = 0.25)						
2.97.5 86+						
Luukinen 2006	−0.10410841	0.1411547	144	150	7.0%	−0.10 [−0.38, 0.17]
Subtotal (95% CI)			**144**	**150**	**7.0%**	**−0.10 [−0.38, 0.17]**
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.74 (P = 0.46)						
Total (95% CI)			**1627**	**1599**	**100.0%**	**−0.11 [−0.19, −0.02]**
Heterogeneity: $Tau^2 = 0.01$; $Chi^2 = 16.65$, df = 13 (P = 0.22); $I^2 = 22\%$						
Test for overall effect: Z = 2.55 (P = 0.01)						
Test for subgroup differences: $Chi^2 = 0.31$, df = 4 (P = 0.99), $I^2 = 0\%$						

Analysis 79: Psychiatric (anxiety and depression); type of visitor subgroups



Analysis 80: Psychiatric (anxiety and depression); number of visits subgroups